Genemedicine Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 23, 2027The maintenance fee for Virus-Pcion Complex Having Enhanced Antitumor Effect by Using Electromagnetic Field (US 10,357,564) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Jun 26, 2027The maintenance fee for Recombinant Adenoviruses and Stem Cells Comprising Same (US 11,850,215) comes due Jun 26, 2027. Unpaid by Dec 27, 2027, it lapses early.
- 1 fee due Oct 30, 2027The maintenance fee for PH-sensitive and bioreducible polymer-virus complex for cancer treatment (US 11,970,715) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,067,567 | Modified Tert Promoter with Enhanced Tumor-Specificity and Strength and Recombinant Vector Comprising the Same In force · High confidence | In force | High confidence | |
| US 8,298,790 | Methods for Effectively Coexpressing IL-12 and IL-23 In force · High confidence | In force | High confidence | |
| US 9,657,069 | Anti-Cancer Compositions Containing WNT Decoy Receptor In force · High confidence | In force | High confidence | |
| US 9,689,000 | Gene Delivery System Having Enhanced Tumor-Specific Expression, and Recombinant Gene Expression Regulating Sequence In force · High confidence | In force | High confidence | |
| US 11,970,715 | PH-sensitive and bioreducible polymer-virus complex for cancer treatment In force · From the USPTO record | In force | From the USPTO record | |
| US 9,974,818 | Ppsa and Pspa Polymer-Virus Complex and Pharmaceutical Compositions Comprising the Same In force · High confidence | In force | High confidence | |
| US 10,722,587 | Composition for Intracellular Delivery Containing Adenovirus Protein VI-Derived Peptide and Anticancer Pharmaceutical Composition Containing Same In force · High confidence | In force | High confidence | |
| US 11,174,465 | Ph-Sensitive and Bioreducible Polymer-Virus Complex for Cancer Treatment In force · High confidence | In force | High confidence | |
| US 11,000,590 | Virus-Pcion Complex Having Enhanced Antitumor Effect by Using Electromagnetic Field In force · High confidence | In force | High confidence | |
| US 10,357,564 | Virus-Pcion Complex Having Enhanced Antitumor Effect by Using Electromagnetic Field In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 6 lapsed for an unpaid fee · 10 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 4 abandoned · 1 no status recorded